Supplementary Material 1. Reporting information (original S2.2)

S2.2 Finalized reporting information

STROBE/RECORD 1 and STROBE 2–5

The title, abstract, Introduction and Methods identify secondary aggregate-table appraisal, source coverage 2014–2020 and quantitative period 2018–2020.

STROBE 6 and RECORD 6.1, 6.3, 7.1, 13

Methods and S1.1 specify table eligibility and provenance. Study units are published cells, not recruited participants.

STROBE 7–8 and RECORD 6.2

Methods and S1 retain labels, definitions, source locations and denominators. A versioned crosswalk and external coding validation are unavailable.

STROBE 9–12 and RECORD 12.1–12.2

Methods and S1.5/S2.1 describe bias, missingness, descriptive formulas, optional-percent parsing, full-table closure and arithmetic verification.

STROBE 14–17

Results and S1.2–S1.3/S1.5 report counts, source or calculated percentages, denominator definitions and age strata. Missing contingency cells were not imputed.

STROBE 18–21 and RECORD 19.1

Discussion distinguishes source findings, contextual evidence, future proposals and limitations of passive reporting and uncertain coding.

STROBE 22

Manuscript Declarations and the separate title page specify no specific grant, no other financial/in-kind support, no funder role and no applicable grant/award numbers.

RECORD 22.1

S1 retains source-linked extracts; supplied text files provide executable current code and data/results. No prospective registration or public-repository deposit is claimed.

Ethics and consent

Public anonymous aggregate data only; no individual records, participant contact or intervention. Ethics approval was not obtained and no formal exemption was sought or granted.

AI and independent checking

The main disclosure distinguishes language, data processing and automated verification. The original independent data check was author-confirmed; new wording and analyses are not represented as independently reviewed.

Supplementary Material 1. Reporting information (continued)

Authorship and conflicts

The manuscript and title page declare no financial, personal or other conflicts. The title page provides sole-author information and the permission-confirmed acknowledgment. Final approval of the revision remains the author's responsibility.

Guidance references

von Elm et al. STROBE. Ann Intern Med. 2007;147:573–577. doi:10.7326/0003-4819-147-8-200710160-00010.

Benchimol et al. RECORD. PLoS Med. 2015;12:e1001885. doi:10.1371/journal.pmed.1001885.

World Health Organization. Guidelines for establishing a poison centre. 2020. https://www.who.int/publications/i/item/9789240009523

Supplementary Material 2. Source inventory and availability (original S1.1)

S1 Supplementary Data and Sources

S1.1 Source inventory and availability

Data interpretation limits. These published aggregates describe source-defined reports, not confirmed poisoning, population incidence or verified unique individuals. Repeated contacts and multi-agent reporting cannot be resolved at person level. Original categories, combinations, salt forms and adjacent groups are retained separately; equal counts or similar labels do not establish equivalent record sets, and repeated table entries are not added to pooled totals. Missing entries mean “not identified” or “not specified”, not zero or absence from the institutional database. Each percentage retains its source population and denominator; differing classification levels, age bands and comparator counting units limit direct comparisons. Unresolved differences are reported without inferring database error. The available tables cannot establish causes of annual change, including pandemic effects, or target-group clinical outcomes.

Source: the 728-page UZEM 2014-2020 compendium cited in the manuscript. The inventory covers 24 core tables for the two target groups, selected agents and denominators; additional contextual sources appear below. Eligibility and search procedures are described in the manuscript Methods.

Reporting units. Calls are service contacts (incoming and answered calls are separate measures); cases are the source units used in case totals. Exposures describe substance contact. Substances denote agents or products, while group/agent records denote counts under a published label. The 45 group-level and 51 agent-level extraction rows are analytical entries with provenance, not 96 additional reports. Human-health-product denominators remain distinct from all-case denominators; agent lists are not assumed to reconstruct group or case totals. HHP = human-health products.

Appraisal framework

The seven domains assess usability for the specified comparisons. STROBE [1] and RECORD [2] informed the reporting rationale; WHO poison-centre guidance [3] informed the clinical reporting context. The framework and guidance mapping were nonprospective, unregistered, unweighted and unvalidated; no overall score was assigned.

Domain	Operational check and analytical decision	Reporting basis
Temporal availability	Search chapters, appendices and indexes for target variables; distinguish general from topic-specific series and compare like-for-like periods/populations.	STROBE 5, 8 [1]
Denominators	Identify the stated population and total in headings, footnotes or supporting tables. Recalculate only with explicit totals and flag changes between all-case and human-health-product populations.	STROBE 12(c), 14(b): missingness [1]; denominator comparability is a study-defined rule.
Category and agent definitions	Retain original labels and classification levels, combinations and salt forms; require a documented mapping before treating labels as equivalent.	STROBE 7-8; RECORD 7.1 [1, 2]
Repeated reporting	Compare full distributions, top lists and age-specific tables; flag repeated entries and exclude them from pooled totals.	Adaptation of RECORD 12.2 to table entries, not person-level deduplication [2].
Numerical consistency	Compare table totals and narrative, recalculate percentages and check full-table sums; retain conflicting values with their locations.	RECORD 12.2 [2]; closure/cross-table tests are study-defined.
Clinical linkage	Seek target-group links to dose, intent, severity, treatment, disposition and outcomes. None were identified; Tables 65 and 87 describe broader-population severity.	STROBE 7, 15 [1]. RECORD 12.3 database linkage was not undertaken [2].
Coding changes	Review software/coding descriptions and mappings; identify potential discontinuities without assigning a causal effect on reported counts.	RECORD 19.1 [2]

The AI-assisted extraction and appraisal used table cells as quantitative units and headings, footnotes and contextual passages for interpretation. Usability was assigned to each variable/comparison, not as an overall table score: a count may be usable while its percentage is unsuitable for an across-year comparison. Verification status is reported in S2.1. Purposive comparator selection and the appraisal approach may introduce selection or interpretive bias. Proposed reporting improvements were not tested.

Supplementary Material 2. Source inventory and availability (continued)

Core source inventory

Source: table number / PDF page(s) (printed page(s)). HHP = human-health products.

Year	Source (Table/Page)	Population / denominator	Analytical role	Notes
2018	T12 / 50-58 (19-27)	All UZEM cases	Full poison-group distribution	Primary general target-group counts.
2018	T13 / 59 (28)	All UZEM cases	Top 10 poison groups	Repeat of relevant Table 12 counts.
2018	T15 / 61-62 (30-31)	HHP; n = 153,623	Top 50 ATC-named HHP agents	HHP denominator; differs from 2019-2020 mixed top lists.
2018	T22 / 70 (39)	All cases aged 0-5; n = 61,272	Top five poison groups	Denominator: Table 19; PDF 67 / printed 36.
2018	T23 / 71 (40)	HHP aged 0-5; n = 36,561	Top five poison groups	Denominator: Table 21; PDF 69 / printed 38. Numerators match Table 22.
2019	T43 / 98-100 (67-69)	All UZEM cases; n = 217,936	Top 50 product/agent/poison-group records	Mixed classification levels.
2019	T44 / 101-110 (70-79)	All UZEM cases	Full poison-group distribution	Primary general target-group counts.
2019	T45 / 111 (80)	All UZEM cases	Top 10 poison groups	Repeat of relevant Table 44 counts.
2019	T46 / 112 (81)	Cases aged 0-5	Top 10 poison groups	Age denominator not printed.
2019	T47 / 113 (82)	Cases aged 6-12	Top 10 poison groups	Age denominator not printed.
2019	T48 / 114 (83)	Cases aged 13-20	Top 10 poison groups	No corresponding published table for age ≥21.
2020	T68 / 178-179 (147-148)	All UZEM cases; n = 187,528	Top 50 product/agent/poison-group records	Mixed classification levels.
2020	T69 / 180-187 (149-156)	All UZEM cases	Full poison-group distribution	Primary general target-group counts.
2020	T70 / 188 (157)	All UZEM cases	Top 10 poison groups	Repeat of relevant Table 69 counts.
2020	T71 / 189 (158)	Cases aged 6-12	Top 10 poison groups	Denominator not printed; all rows consistent with n = 6,875 after rounding.
2020	T72 / 190 (159)	Cases aged 13-20	Top 10 poison groups	Age denominator not printed.
2020	T73 / 191 (160)	Cases aged ≥21	Top 10 poison groups	Age denominator not printed.
2020	T89 / 316 (285)	Cases aged 0-5	Poison upper-group distribution	Denominators: 49,656 all cases; 26,663 HHP records.
2020	T90 / 317-318 (286-287)	All cases aged 0-5	Top 50 product/agent/poison-group records	Selected counts recur in Table 95 with different labels and denominators.
2020	T91 / 319-329 (288-298)	All cases aged 0-5	Full poison-group distribution	Primary paediatric all-case target-group counts.
2020	T92 / 330 (299)	All cases aged 0-5	Top 10 poison groups	Repeat of relevant Table 91 counts.
2020	T93 / 331-333 (300-302)	HHP aged 0-5	Full HHP poison-group distribution	Same target-group numerators as Table 91; different denominator.
2020	T94 / 334 (303)	HHP aged 0-5	Top 10 HHP poison groups	Repeat of relevant Table 93 counts.
2020	T95 / 335-336 (304-305)	HHP aged 0-5	Top 50 HHP active agents	Selected counts match Table 90; possible repeats, not pooled.

Supplementary Material 2. Source inventory and availability (continued)

Year-by-variable availability

Variable	2014-2017 (each year)	2018-2020 (each year)
All-case totals	A	A
Human-health-product totals	A	A
General analgesics distribution	N	A
General anti-inflammatory/antirheumatic distribution	N	A
General agent rankings	N	A

A: available. N: not identified. This matrix records availability only; comparison-specific consequences and proposals are in manuscript Table 3.

Contextual sources and early-year discrepancies

Reporting-environment sources were 2018 Tables 1-10, 2019 Tables 33-41 and 49-51, and 2020 Tables 54-77; overlaps with the core inventory are not additional datasets. HHP denominator sources are Tables 11 (PDF 49 / printed 18), 42 (97 / 66) and 67 (177 / 146). For 2018 age 0-5, Tables 19 and 21 provide 61,272 all cases and 36,561 HHP records respectively; the latter is the full HHP total, not its five-category subtotal.

Table 58 (PDF 168 / printed 137) reports 97 cases with unknown age in 2020. Group-specific age-missingness counts are unavailable, so the target-group residuals of 11 and 22 remain unattributed. Broader severity data appear in Tables 65 (175 / 144) and 87 (314 / 283). Antidepressant, agricultural-chemical, scorpion and L-thyroxine appendix series were screened but not substituted for the target groups.

Tables 1 and 101 contain the conflicting retrospective totals below. These publication inconsistencies are distinguished from analytical limitations such as changed denominators or unavailable clinical cross-tabulations. S1.3 separately records the non-descending count sequence in Table 90 while preserving source positions.

Year	Table 1 total	Table 101 total	Difference (T1 − T101)	Table 102 HHP count	Table 102 reported %
2014	199,679	199,681	−2	136,290	68.25
2015	201,646	201,608	38	135,889	67.41
2016	218,025	218,010	15	145,850	66.90
2017	213,534	213,533	1	150,551	70.50

Sources: Table 1, PDF 38 / printed 7; Table 101, 428 / 397; Table 102, 429 / 398. For 2015, Table 101 gives 201,608, its first explanatory paragraph 201,681, and Graph 82 and its explanation 201,608. Values are retained as published; the true institutional total is unresolved.

The 2015 HHP count divided by the Table 101 total rounds to 67.40%, compared with the published 67.41%. These general totals do not provide missing target-group numerators. The foreword mentions a separate detailed 2017 activity report that is not an annual chapter of this compendium.

2017 age band	Source (Table/Page)	All-case count	Reported %
0-6	T186 / 686 (655)	64,862	30.38
7-18	T186 / 686 (655)	44,067	20.64
>18	T186 / 686 (655)	104,605	48.99

These counts sum to 213,534. Table 186 is in the L-thyroxine appendix but describes all UZEM cases. Its age boundaries differ from the later target-group tables; published percentages sum to 100.01% through rounding.

Supplementary Material 3. Group-level data (original S1.2)

S1.2 Group-level data

All 45 group-level extraction rows are retained. Counts and percentages are source-reported; Notes combine extraction role and repeated-reporting information.

Source: table number / PDF page (printed page). N is the source denominator; “not specified” identifies an unprinted denominator count. The general interpretation limits in S1.1 apply throughout.

Notes identify extraction role and repeated reporting. Top-10 repeats are retained for traceability and excluded from pooled totals. Adjacent pain-treatment and opiate categories remain separate from the two primary groups.

Year / population	Source (Table/Page)	Source label	Count	%	Denominator / N	Notes
2018; All cases	T12 / 50 (19)	ANALJEZİKLER	13,423	6.18	All cases; N=217,323	Primary general distribution
2018; All cases	T12 / 50 (19)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	20,560	9.46	All cases; N=217,323	Primary general distribution
2018; All cases	T13 / 59 (28)	ANALJEZİKLER	13,423	6.18	All cases; N=217,323	Top-10 repeat of T12
2018; All cases	T13 / 59 (28)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	20,560	9.46	All cases; N=217,323	Top-10 repeat of T12
2018; Age 0-5	T22 / 70 (39)	ANALJEZİKLER	3,229	5.27	All age 0-5 cases; N=61,272	Primary paediatric distribution
2018; Age 0-5	T22 / 70 (39)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	5,021	8.19	All age 0-5 cases; N=61,272	Primary paediatric distribution
2018; Age 0-5 HHP	T23 / 71 (40)	ANALJEZİKLER	3,229	8.83	Age 0-5 HHP; N=36,561	Same count as T22; different denominator
2018; Age 0-5 HHP	T23 / 71 (40)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	5,021	13.73	Age 0-5 HHP; N=36,561	Same count as T22; different denominator
2019; All cases	T44 / 101 (70)	ANALJEZİKLER	13,744	6.31	All cases; N=217,936	Primary general distribution
2019; All cases	T44 / 101 (70)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	23,755	10.90	All cases; N=217,936	Primary general distribution
2019; All cases	T45 / 111 (80)	ANALJEZİKLER	13,744	6.31	All cases; N=217,936	Top-10 repeat of T44
2019; All cases	T45 / 111 (80)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	23,755	10.90	All cases; N=217,936	Top-10 repeat of T44
2019; Age 0-5	T46 / 112 (81)	ANALJEZİKLER	3,376	5.48	Age-specific cases; N=not specified	Age-specific; denominator not printed
2019; Age 0-5	T46 / 112 (81)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	5,475	8.89	Age-specific cases; N=not specified	Age-specific; denominator not printed
2019; Age 6-12	T47 / 113 (82)	ANALJEZİKLER	400	4.53	Age-specific cases; N=not specified	Age-specific; denominator not printed
2019; Age 6-12	T47 / 113 (82)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	501	5.68	Age-specific cases; N=not specified	Age-specific; denominator not printed

Supplementary Material 3. Group-level data (continued)

Year / population	Source (Table/Page)	Source label	Count	%	Denominator / N	Notes
2019; Age 13-20	T48 / 114 (83)	ANALJEZİKLER	4,470	9.02	Age-specific cases; N=not specified	Age-specific; denominator not printed
2019; Age 13-20	T48 / 114 (83)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	6,862	13.85	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; All cases	T69 / 180 (149)	ANALJEZİKLER	10,619	5.66	All cases; N=187,528	Primary general distribution
2020; All cases	T69 / 180 (149)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	18,395	9.81	All cases; N=187,528	Primary general distribution
2020; All cases	T70 / 188 (157)	ANALJEZİKLER	10,619	5.66	All cases; N=187,528	Top-10 repeat of T69
2020; All cases	T70 / 188 (157)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	18,395	9.81	All cases; N=187,528	Top-10 repeat of T69
2020; Age 6-12	T71 / 189 (158)	ANALJEZİKLER	259	3.77	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 6-12	T71 / 189 (158)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	307	4.47	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 13-20	T72 / 190 (159)	ANALJEZİKLER	2,986	8.24	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 13-20	T72 / 190 (159)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	4,821	13.30	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 21 or older	T73 / 191 (160)	ANALJEZİKLER	4,946	5.23	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 21 or older	T73 / 191 (160)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	9,517	10.07	Age-specific cases; N=not specified	Age-specific; denominator not printed
2020; Age 0-5	T91 / 319 (288)	ANALJEZİKLER	2,417	4.87	All age 0-5 cases; N=49,656	Primary paediatric distribution
2020; Age 0-5	T91 / 319 (288)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	3,728	7.51	All age 0-5 cases; N=49,656	Primary paediatric distribution
2020; Age 0-5	T92 / 330 (299)	ANALJEZİKLER	2,417	4.87	All age 0-5 cases; N=49,656	Top-10 repeat of T91
2020; Age 0-5	T92 / 330 (299)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	3,728	7.51	All age 0-5 cases; N=49,656	Top-10 repeat of T91
2020; Age 0-5 HHP	T93 / 331 (300)	ANALJEZİKLER	2,417	9.06	Age 0-5 HHP; N=26,663	Same count as T91; different denominator
2020; Age 0-5 HHP	T93 / 331 (300)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	3,728	13.98	Age 0-5 HHP; N=26,663	Same count as T91; different denominator
2020; Age 0-5 HHP	T94 / 334 (303)	ANALJEZİKLER	2,417	9.06	Age 0-5 HHP; N=26,663	Top-10 repeat of T93
2020; Age 0-5 HHP	T94 / 334 (303)	ANTİİNFLAMATUVARLAR VE ANTİROMATİK ÜRÜNLER	3,728	13.98	Age 0-5 HHP; N=26,663	Top-10 repeat of T93

Supplementary Material 3. Group-level data (continued)

Year / population	Source (Table/Page)	Source label	Count	%	Denominator / N	Notes
2018; All cases	T12 / 53 (22)	EKLEM VE KAS AĞRISINDA KULLANILAN TOPİKAL ÜRÜNLER	320	0.15	All cases; N=217,323	Adjacent pain-treatment group; separate
2018; All cases	T12 / 54 (23)	İSKELET KASINI GEVŞETEN İLAÇLAR	4,054	1.87	All cases; N=217,323	Adjacent pain-treatment group; separate
2018; All cases	T12 / 56 (25)	OPİADLAR	95	0.04	All cases; N=217,323	Adjacent opiate category; medicinal use unspecified
2019; All cases	T44 / 101 (70)	İSKELET KASINI GEVŞETEN İLAÇLAR	3,393	1.56	All cases; N=217,936	Adjacent pain-treatment group; separate
2019; All cases	T44 / 103 (72)	EKLEM VE KAS AĞRISINDA KULLANILAN TOPİKAL ÜRÜNLER	294	0.13	All cases; N=217,936	Adjacent pain-treatment group; separate
2019; All cases	T44 / 106 (75)	OPİADLAR	72	0.03	All cases; N=217,936	Adjacent opiate category; medicinal use unspecified
2020; All cases	T69 / 182 (151)	EKLEM VE KAS AĞRISINDA KULLANILAN TOPİKAL ÜRÜNLER	263	0.14	All cases; N=187,528	Adjacent pain-treatment group; separate
2020; All cases	T69 / 183 (152)	İSKELET KASINI GEVŞETEN İLAÇLAR	2,659	1.42	All cases; N=187,528	Adjacent pain-treatment group; separate
2020; All cases	T69 / 185 (154)	OPİADLAR	71	0.04	All cases; N=187,528	Adjacent opiate category; medicinal use unspecified

Supplementary Material 4. Agent-level data (original S1.3)

S1.3 Agent-level data

All 51 agent-level extraction rows are retained, including source labels and list positions. Notes combine classification and repeated-reporting information.

Source: table number / PDF page (printed page). N is the source denominator; “not specified” identifies an unprinted denominator count. The general interpretation limits in S1.1 apply throughout.

Table 15 (2018) uses ATC-named human-health products and the human-health-product denominator; Tables 43 (2019) and 68 (2020) mix product, ingredient and poison-group labels and use all-case denominators. These are year-specific lists, not a harmonized annual agent series.

Salt-specific, combination and therapeutic-function categories retain separate entries. Possible repeats are identified in Notes and excluded from pooling.

Year / population	Source (Table/Page)	Source label	Pos.	Count	%	Denominator / N	Notes
2018; All ages HHP	T15 / 61 (30)	PARASETAMOL	2	7,988	5.20	HHP; N=153,623	Single-ingredient label
2018; All ages HHP	T15 / 61 (30)	DİKLOFENAK DİETİLAMONYUM TUZU	4	5,339	3.48	HHP; N=153,623	Salt-specific; separate from later labels
2018; All ages HHP	T15 / 61 (30)	DEKSKETOPROFEN TROMETAMOL	6	4,027	2.62	HHP; N=153,623	Salt-specific; separate from later labels
2018; All ages HHP	T15 / 61 (30)	ASETAMİNOFEN + PAMABROM + PİRİLAMİN MALEAT	9	2,704	1.76	HHP; N=153,623	Combination; separate
2018; All ages HHP	T15 / 61 (30)	FLURBİPROFEN	11	2,332	1.52	HHP; N=153,623	Single-ingredient label
2018; All ages HHP	T15 / 61 (30)	İBUPROFEN	12	2,291	1.49	HHP; N=153,623	Single-ingredient label
2018; All ages HHP	T15 / 61 (30)	NAPROKSEN	14	2,188	1.42	HHP; N=153,623	Single-ingredient label
2018; All ages HHP	T15 / 61 (30)	İBUPROFEN, KOMBİNASYONLARI	22	1,354	0.88	HHP; N=153,623	Combination; separate
2018; All ages HHP	T15 / 61 (30)	ASETİLSALİSİLİK ASİT (ANTİTROMBOTİK)	25	1,237	0.81	HHP; N=153,623	Antithrombotic aspirin; separate
2018; All ages HHP	T15 / 62 (31)	BUTİLSKOPOLAMİN VE ANALJEZİKLER	26	1,230	0.80	HHP; N=153,623	Analgesic combination; separate
2018; All ages HHP	T15 / 62 (31)	FENİRAMİDOL HİDROKLORÜR	28	1,226	0.80	HHP; N=153,623	Muscle relaxant; salt-specific
2018; All ages HHP	T15 / 62 (31)	ETODOLAK	31	1,086	0.71	HHP; N=153,623	Single-ingredient label
2018; All ages HHP	T15 / 62 (31)	ASETİLSALİSİLİK ASİT (ANALJEZİK)	43	824	0.54	HHP; N=153,623	Analgesic aspirin; separate
2019; All cases	T43 / 98 (67)	PARASETAMOL	1	8,504	3.90	All cases; N=217,936	Single-ingredient label
2019; All cases	T43 / 98 (67)	DİKLOFENAK	6	5,109	2.34	All cases; N=217,936	Broader label than 2018

Supplementary Material 4. Agent-level data (continued)

Year / population	Source (Table/Page)	Source label	Pos.	Count	%	Denominator / N	Notes
2019; All cases	T43 / 98 (67)	DEKSKETOPROFEN	7	4,537	2.08	All cases; N=217,936	Broader label than 2018
2019; All cases	T43 / 98 (67)	İBUPROFEN, KOMBİNASYONLARI	9	3,987	1.83	All cases; N=217,936	Combination; separate
2019; All cases	T43 / 98 (67)	PARASETAMOL, KOMBİNASYONLAR HARİÇ PSİKOLEPTİKLER	14	2,620	1.20	All cases; N=217,936	Ambiguous label; retained verbatim
2019; All cases	T43 / 98 (67)	İBUPROFEN	15	2,455	1.13	All cases; N=217,936	Single-ingredient label
2019; All cases	T43 / 99 (68)	FLURBİPROFEN	22	2,042	0.94	All cases; N=217,936	Single-ingredient label
2019; All cases	T43 / 99 (68)	NAPROKSEN	23	2,024	0.93	All cases; N=217,936	Single-ingredient label
2019; All cases	T43 / 100 (69)	ASETİLSALİSİLİK ASİT	37	1,285	0.59	All cases; N=217,936	Function unspecified; separate from 2018 aspirin rows
2019; All cases	T43 / 100 (69)	FENİRAMİDOL	40	1,185	0.54	All cases; N=217,936	Muscle relaxant; broader label than 2018
2019; All cases	T43 / 100 (69)	ETODOLAK	45	1,097	0.50	All cases; N=217,936	Single-ingredient label
2020; All cases	T68 / 178 (147)	PARASETAMOL	1	6,648	3.55	All cases; N=187,528	Single-ingredient label
2020; All cases	T68 / 178 (147)	DİKLOFENAK	6	4,175	2.23	All cases; N=187,528	Broader label than 2018
2020; All cases	T68 / 178 (147)	DEKSKETOPROFEN	7	3,790	2.02	All cases; N=187,528	Broader label than 2018
2020; All cases	T68 / 178 (147)	İBUPROFEN, KOMBİNASYONLARI	12	2,790	1.49	All cases; N=187,528	Combination; separate
2020; All cases	T68 / 178 (147)	PARASETAMOL, KOMBİNASYONLAR HARİÇ PSİKOLEPTİKLER	17	1,969	1.05	All cases; N=187,528	Ambiguous label; retained verbatim
2020; All cases	T68 / 178 (147)	NAPROKSEN	21	1,854	0.99	All cases; N=187,528	Single-ingredient label
2020; All cases	T68 / 179 (148)	FLURBİPROFEN	29	1,553	0.83	All cases; N=187,528	Single-ingredient label
2020; All cases	T68 / 179 (148)	İBUPROFEN	31	1,482	0.79	All cases; N=187,528	Single-ingredient label
2020; All cases	T68 / 179 (148)	ASETİLSALİSİLİK ASİT	39	1,155	0.62	All cases; N=187,528	Function unspecified; separate from 2018 aspirin rows
2020; All cases	T68 / 179 (148)	FENİRAMİDOL	46	908	0.48	All cases; N=187,528	Muscle relaxant; broader label than 2018
2020; Age 0-5 all cases	T90 / 317 (286)	PARASETAMOL	2	2,003	4.03	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 all cases	T90 / 317 (286)	DİKLOFENAK	3	1,466	2.95	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 all cases	T90 / 317 (286)	İBUPROFEN	14	732	1.47	All age 0-5 cases; N=49,656	Count matches T95; different denominator

Supplementary Material 4. Agent-level data (continued)

Year / population	Source (Table/Page)	Source label	Pos.	Count	%	Denominator / N	Notes
2020; Age 0-5 all cases	T90 / 317 (286)	DEKSKETOPROFEN	20	495	1.00	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 all cases	T90 / 318 (287)	ASETİLSALİSİLİK ASİT	27	337	0.68	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 all cases	T90 / 318 (287)	FLURBİPROFEN	31	298	0.60	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 all cases	T90 / 318 (287)	İBUPROFEN, KOMBİNASYONLARI	36	256	0.52	All age 0-5 cases; N=49,656	Count matches T95; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	ASETAMİNOFEN	1	2,003	7.51	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	DİKLOFENAK DİETİLAMİN	2	1,466	5.50	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	İBUPROFEN	6	732	2.75	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	DEKSKETOPROFEN TROMETAMİN	9	495	1.86	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	ASETİLSALİSİLİK ASİT (ATC: B01AC06)	14	337	1.26	Age 0-5 HHP; N=26,663	Antithrombotic; count matches T90
2020; Age 0-5 HHP	T95 / 335 (304)	FLURBİPROFEN	15	298	1.12	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 335 (304)	İBUPROFEN, KOMBİNASYONLAR	17	256	0.96	Age 0-5 HHP; N=26,663	Count matches T90; different denominator
2020; Age 0-5 HHP	T95 / 336 (305)	ASETİLSALİSİLİK ASİT VE TÜREVLERİ (ATC: N02BA01)	28	151	0.57	Age 0-5 HHP; N=26,663	Analgesic aspirin; separate
2020; Age 0-5 HHP	T95 / 336 (305)	NAPROKSEN	31	147	0.55	Age 0-5 HHP; N=26,663	Single ingredient; absent from T90 top 50
2020; Age 0-5 HHP	T95 / 336 (305)	ASETAMİNOFEN + PAMABROM + PİRİLAMİN	34	142	0.53	Age 0-5 HHP; N=26,663	Combination; separate; absent from T90 top 50

Pos. = source position. In Table 90 (PDF 317, printed 286), “İNSAN SAĞLIĞINDA KULLANILAN ARA ÜRÜNLER” has 949 records at position 18, compared with 946 at position 12 and 584 at position 17; the original sequence is retained.

Nonappearance in a top-50 list is not treated as zero. The reason for the Table 90 omissions is unresolved.

Supplementary Material 5. Verification record (original S2.1)

S2.1 Current verification record

The 7 October 2026 rerun used the supplied 728-page government PDF and submitted supplementary extracts. Government-PDF SHA-256: 65ca7519c998c19b690fe7f342ace568f0d3e4d34d7e0e31945905f2d3af8261.

All 96 selected label/count/percentage combinations matched their source pages: 45 group-level and 51 agent-level rows. All 84 percentages with explicit denominators agreed within a 0.005 percentage-point rounding tolerance. Twelve denominator fields remain unspecified and were not reconstructed. Original list positions were retained, but the automated match does not independently adjudicate rankings or coding.

Complete-table closure: T12, 299 rows / 217,323 records; T44, 297 / 217,936; T69, 292 / 187,528; T91, 271 / 49,656; T93, 83 / 26,663. The five distributions contain 1,242 rows in total and each sum equals its published total.

Current parser correction

A baseline regex excluding a percent suffix omitted KÜLTÜR MANTARLARI (509; 0.23%) in 2019 Table 44, source PDF page 102. Accepting an optional suffix restored all 297 rows and the 217,936 total. Principal totals and the 96 selected rows were unchanged. The earlier supplied text described a three-row/794-record omission; that implementation was unavailable and the historical account is not claimed as reproduced.

Verification evidence

The submitted verification evidence consists of the executed current code, source-linked selected and full-table extracts, explicit-denominator recalculation, full-table sums, source hash, and current outputs. An unavailable historical archive or test run is not used to support these results.

Independent check and reproducibility

The author confirmed the independent second-researcher check of the original manuscript and supplementary data, with no errors requiring correction. That check does not represent independent review of newly added text or analyses. Current automated checks are separate. Runtime: Python 3.12.14, pypdf 6.10.0, pdfplumber 0.11.9. The supplied verification code, data and README document rerunning the checks. Source-text and arithmetic agreement does not validate the underlying database, coding decisions, clinical ascertainment or completeness of reporting.

Supplementary Material 6. Comparator definitions (original S1.4)

S1.4 Selected comparator definitions and observation periods

Seven illustrative comparator study/system entries were selected purposively to cover the main Discussion themes: Turkish context, counting units and denominators, product and error circumstances, clinical outcome sources, reporting pathways, and temporal design. This is not a systematic or exhaustive comparison. Only the comparator definitions shown below are supplied; the unavailable historical comparator matrix is not claimed as reconstructed or included in the archive. Bibliographic details remain in the manuscript.

Study/system	Coverage	Unit and denominator	Relevance to this appraisal
Current UZEM analysis	Türkiye, 2018-2020 quantitative period	Published national tables; source-defined cases, with human-health-product records as a secondary denominator.	Reference framework; the two source medication groups remain separate.
Hocaoglu et al., 2007	İzmir, 1993-2004	Regional poison-center exposure records; medicine-related exposure calls.	Historical Turkish context; older regional coverage and different analgesic grouping.
Gummin et al., 2019-2021: NPDS reports	United States, 2018-2020	Human exposure cases, substance entries and information contacts; table-specific case or substance denominators.	Year-aligned reporting structure; class membership and multi-substance counting differ.
Brass et al., 2019	United States, 2007-2016; age ≥12 years	NPDS therapeutic-misuse exposures to nonprescription acetaminophen combinations; population- and sales-normalized rates.	Illustrates product and intent detail beyond broad UZEM categories.
Eluri et al., 2018	United States, 2000-2012	NPDS medication-error exposure records; error-specific, subgroup and population denominators.	Supports error-circumstance fields; selected medication-error population.
Cairns et al., 2019	Australia: poison center 2004-2017; admissions/deaths 2007-2008 to 2016-2017	Intentional single-ingredient paracetamol overdoses; separate hospital-admission and coronial-death series.	Complementary outcome surveillance from separate, unlinked sources.
Major et al., 2016	United States: NPDS 2008-2012; NEISS-CADES 2004-2012; NIS 1998-2011	Poison-center calls, sampled emergency-department events and hospital discharges; dataset-specific estimates, population and sales.	Multiple care settings and reporting pathways; sampling and event definitions differ.
Karami et al., 2023	United States, Jan 2015-Apr 2021; age <18 years	Monthly NPDS nonprescription acetaminophen, ibuprofen, aspirin and naproxen counts by intent, age and sex.	Monthly pediatric, product-specific design; UZEM provides only three annual group counts.

Supplementary Material 7. Annual denominator summary (original S1.5)

S1.5 Annual denominator summary

Counts are source-reported; percentages are calculated as 100 × group count/denominator and rounded to two decimals. All-case and human-health-product (HHP) populations are distinct. The two groups remain separate; coding stability is unverified.

Year	Published group	Count	All-case total	HHP total	% all cases	% HHP
2018	Analgesics	13,423	217,323	153,623	6.18	8.74
2018	Anti-inflammatory / antirheumatic	20,560	217,323	153,623	9.46	13.38
2019	Analgesics	13,744	217,936	153,427	6.31	8.96
2019	Anti-inflammatory / antirheumatic	23,755	217,936	153,427	10.90	15.48
2020	Analgesics	10,619	187,528	122,995	5.66	8.63
2020	Anti-inflammatory / antirheumatic	18,395	187,528	122,995	9.81	14.96

Sources: group counts and all-case totals, Tables 12, 44, and 69; HHP totals, Tables 11, 42, and 67. The all-case percentages support the main annual and secondary pooled summaries; HHP percentages are used in Figure 1.